Abstract
Background: Several studies have shown that religiosity has beneficial effects on health, mortality and pathological conditions; little is known about religiosity in Alzheimers disease and the progression of its cognitive, behavioral and functional symptoms. Our aim was to identify any relationship between religiosity and the progression of cognitive impairment and behavioral disorders in mild-moderate Alzheimers disease, and any relationship between the patients religiosity and the stress in caregivers. Materials and Methods: 64 patients with Alzheimers disease were analyzed at baseline and 12 months later using the Mini-Mental State Examination (MMSE), the Behavioral Religiosity Scale (BRS) and the Francis Short Scale (FSS). Caregivers were also questioned on the patients functional abilities (ADL, IADL), the behavioral disturbances (NPI), and on their stress (NPI-D, CBI). Patients were divided into 2 groups according to BRS: a score of < 24 meant no or low religiosity (LR), while a score of ≥24 meant moderate or high religiosity (HR). Findings: LR patients had worsened more markedly after 12 months in their total cognitive and behavioral test scores. Stress was also significantly higher in the caregivers of the LR group. Global BRS and FSS scores correlated significantly with variations after 1 year in the MMSE (r: 0.50), NPI (r:-0.51), NPI-D (r:-0.55) and CBI (r:-0.62). A low religiosity coincided with a higher risk of cognitive impairment, considered as a 3-point decrease in MMSE score (OR 6.7, CI: 1.8- 24.7). Interpretation: Higher levels of religiosity in Alzheimers dementia seem to correlate with a slower cognitive and behavioral decline, with a corresponding significant reduction of the caregivers burden.
Keywords: Religion, Alzheimer disease, Cognitive functions, Behavioral disturbs, Caregiver
Current Alzheimer Research
Title: Does Religiosity Protect Against Cognitive and Behavioral Decline in Alzheimers Dementia?
Volume: 7 Issue: 5
Author(s): A. Coin, E. Perissinotto, M. Najjar, A. Girardi, E.M. Inelmen, G. Enzi, E. Manzato and G. Sergi
Affiliation:
Keywords: Religion, Alzheimer disease, Cognitive functions, Behavioral disturbs, Caregiver
Abstract: Background: Several studies have shown that religiosity has beneficial effects on health, mortality and pathological conditions; little is known about religiosity in Alzheimers disease and the progression of its cognitive, behavioral and functional symptoms. Our aim was to identify any relationship between religiosity and the progression of cognitive impairment and behavioral disorders in mild-moderate Alzheimers disease, and any relationship between the patients religiosity and the stress in caregivers. Materials and Methods: 64 patients with Alzheimers disease were analyzed at baseline and 12 months later using the Mini-Mental State Examination (MMSE), the Behavioral Religiosity Scale (BRS) and the Francis Short Scale (FSS). Caregivers were also questioned on the patients functional abilities (ADL, IADL), the behavioral disturbances (NPI), and on their stress (NPI-D, CBI). Patients were divided into 2 groups according to BRS: a score of < 24 meant no or low religiosity (LR), while a score of ≥24 meant moderate or high religiosity (HR). Findings: LR patients had worsened more markedly after 12 months in their total cognitive and behavioral test scores. Stress was also significantly higher in the caregivers of the LR group. Global BRS and FSS scores correlated significantly with variations after 1 year in the MMSE (r: 0.50), NPI (r:-0.51), NPI-D (r:-0.55) and CBI (r:-0.62). A low religiosity coincided with a higher risk of cognitive impairment, considered as a 3-point decrease in MMSE score (OR 6.7, CI: 1.8- 24.7). Interpretation: Higher levels of religiosity in Alzheimers dementia seem to correlate with a slower cognitive and behavioral decline, with a corresponding significant reduction of the caregivers burden.
Export Options
About this article
Cite this article as:
Coin A., Perissinotto E., Najjar M., Girardi A., Inelmen E.M., Enzi G., Manzato E. and Sergi G., Does Religiosity Protect Against Cognitive and Behavioral Decline in Alzheimers Dementia?, Current Alzheimer Research 2010; 7 (5) . https://dx.doi.org/10.2174/156720510791383886
DOI https://dx.doi.org/10.2174/156720510791383886 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diverse Functions and Mechanisms of Pericytes in Ischemic Stroke
Current Neuropharmacology The Physiological Characteristics and Transcytosis Mechanisms of the Blood-Brain Barrier (BBB)
Current Pharmaceutical Biotechnology Need for Nutritious Convenience Foods for the Elderly Population: A Review
Current Nutrition & Food Science Anti-HIV Drug Distribution to the Central Nervous System
Current Pharmaceutical Design Aporphines and Alzheimer’s Disease: Towards a Medical Approach Facing the Future
Current Medicinal Chemistry Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry The Role of Microglia in Antibody-Mediated Clearance of Amyloid-Beta from the Brain
CNS & Neurological Disorders - Drug Targets Chronic Diseases and COVID-19: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Substance P and Alzheimer’s Disease: Emerging Novel Roles
Current Alzheimer Research Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases
Current Molecular Medicine Is there a Possible Single Mediator in Modulating Neuroendocrine–thymus Interaction in Ageing?
Current Aging Science Cholinergic Treatment of Traumatic Brain Injury
Current Drug Therapy Vitamins Mediate Immunological Homeostasis and Diseases at the Surface of the Body
Endocrine, Metabolic & Immune Disorders - Drug Targets Effect of Withania somnifera Supplementation on Rotenone-Induced Oxidative Damage in Cerebellum and Striatum of the Male Mice Brain
Central Nervous System Agents in Medicinal Chemistry Are Anti-Angiogenic Drugs Useful in Neurodegenerative Disorders?
CNS & Neurological Disorders - Drug Targets The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases
Current Neuropharmacology Manipulation of Microglial Activation as a Therapeutic Strategy in Alzheimers Disease
Current Medicinal Chemistry Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry How to Get from Here to There: Macrophage Recruitment in Alzheimers Disease
Current Alzheimer Research Oxidative Stress Biology and Cell Injury During Type 1 and Type 2 Diabetes Mellitus
Current Neurovascular Research